LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Listă Acțiuni・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Închisă

SectorSănătate

15.44 2.86

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

15.02

Maxim

15.49

Indicatori cheie
By Trading Economics
Venit	-130B -25B
Vânzări	-99B 1.1T
P/E Medie Sector	39.974 49.888
EPS	0.21
Randament dividend	4.35
Marjă de profit	-2.222
Angajați	47,455
EBITDA	-242B 214B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+39.72% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	4.35% 2.38%

Statistici piață
By TradingEconomics
Capitalizare de piață	-3.7B 48B
Deschiderea anterioară	12.58
Închiderea anterioară	15.44

Sentimentul știrilor

By Acuity

100%

325 / 344 Clasament în Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 mai 2026, 08:59 UTC

Câștiguri

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 ian. 2026, 07:11 UTC

Câștiguri

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 dec. 2025, 03:32 UTC

Principalele dinamici ale pieței

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 oct. 2025, 09:39 UTC

Câștiguri

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 oct. 2025, 07:32 UTC

Câștiguri

Takeda Posts Quarterly Net Loss, Cuts Guidance

13 mai 2026, 06:57 UTC

Câștiguri

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 mai 2026, 06:54 UTC

Câștiguri

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 mai 2026, 06:44 UTC

Câștiguri

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 mai 2026, 06:38 UTC

Câștiguri

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 mai 2026, 06:31 UTC

Câștiguri

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 mai 2026, 06:31 UTC

Câștiguri

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mai 2026, 06:31 UTC

Câștiguri

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 mai 2026, 06:31 UTC

Câștiguri

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 mai 2026, 06:31 UTC

Câștiguri

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mai 2026, 06:31 UTC

Câștiguri

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 ian. 2026, 06:53 UTC

Câștiguri

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 ian. 2026, 06:36 UTC

Câștiguri

Takeda Raises FY Revenue, Net-Profit Views

29 ian. 2026, 06:34 UTC

Câștiguri

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 ian. 2026, 06:33 UTC

Câștiguri

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 ian. 2026, 06:32 UTC

Câștiguri

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 ian. 2026, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 ian. 2026, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 ian. 2026, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 ian. 2026, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 ian. 2026, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 ian. 2026, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 oct. 2025, 07:10 UTC

Câștiguri

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 oct. 2025, 06:50 UTC

Câștiguri

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 oct. 2025, 06:49 UTC

Câștiguri

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 oct. 2025, 06:48 UTC

Câștiguri

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Comparație

Modificare preț

Takeda Pharmaceutical Co Ltd ADR Așteptări

Obiectiv de preț

By TipRanks

39.72% sus

Prognoză pe 12 luni

Medie 21 USD 39.72%

Maxim 21 USD

Minim 21 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTakeda Pharmaceutical Co Ltd ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Takeda Pharmaceutical Co Ltd ADR - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.